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Abstract
Background: By tradition colloid solutions have been used to obtain fast circulatory stabilisation in shock, but high
molecular weight hydroxyethyl starch (HES) may cause acute kidney failure in patients with severe sepsis. Now lower
molecular weight HES 130/0.4 is the preferred colloid in Scandinavian intensive care units (ICUs) and 1
st choice fluid
for patients with severe sepsis. However, HES 130/0.4 is largely unstudied in patients with severe sepsis.
Methods/Design: The 6S trial will randomise 800 patients with severe sepsis in 30 Scandinavian ICUs to masked fluid
resuscitation using either 6% HES 130/0.4 in Ringer’s acetate or Ringer’s acetate alone. The composite endpoint of 90-
day mortality or end-stage kidney failure is the primary outcome measure. The secondary outcome measures are
severe bleeding or allergic reactions, organ failure, acute kidney failure, days alive without renal replacement therapy
or ventilator support and 28-day and 1/2- and one-year mortality. The sample size will allow the detection of a 10%
absolute difference between the two groups in the composite endpoint with a power of 80%.
Discussion: The 6S trial will provide important safety and efficacy data on the use of HES 130/0.4 in patients with
severe sepsis. The effects on mortality, dialysis-dependency, time on ventilator, bleeding and markers of
resuscitation, metabolism, kidney failure, and coagulation will be assessed.
Trial Registration: ClinicalTrials.gov: NCT00962156
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1Department of Intensive Care, Centre of Clinical Intervention Research,
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Intravascular fluids are the mainstay treatment for
resuscitation of patients with severe sepsis. By tradition,
colloids have been used to obtain fast circulatory stabili-
sation, but there are only few trials with patient-centred
outcome measures on fluid resuscitation of septic
patients. The Surviving Sepsis Campaign recommends
either colloids or crystalloids [1], but high molecular
weight hydroxyethyl starch (HES) may cause acute kid-
ney failure (AKF) in patients with severe sepsis as
observed in a recent meta-analysis [2]. The three largest
trials in this analysis studied HES 200/0.6 (MW in kDa/
substitution ratio - hydroxyethyl groups per glucose),
but found divergent results with respect to kidney fail-
ure with this formulation of starch [3-5]. All these trials
had methodological weaknesses [6,7], and two large
cohort studies in ICU patients also showed divergent
results with respect to the risk of adverse renal effects of
starch treatment [8,9].
If HES contributes to AKF in severe sepsis, this is of
importance as AKF is an independent risk factor for death
in these patients [10-13]. Furthermore, if AKF progresses
to end-stage kidney disease, prolonged renal replacement
therapy will inflict burden to patients and society.
High molecular weight HES also causes coagulopathy
and bleeding and increases the rate of transfusion dur-
ing major surgery [14], but effects in ICU patients are
largely unstudied.
Two Cochrane meta-analyses have been published on
colloid use in critically ill patients in general. One com-
pared colloids with crystalloids [15], but there were few
trials on HES. Therefore, reliable conclusions cannot be
drawn. The other analysis included a comparison
between albumin and high molecular weight HES. In
this, a relative risk reduction (RRR) greater than 20%
could be rejected, but the 14% RRR observed in this
analysis with the use of HES could not be rejected [16].
As the effects of albumin and crystalloids are likely to
be equal [15], an alternative hypothesis may be that high
molecular weight HES reduces the risk of death by 10 -
20% compared to crystalloids.
However the high molecular weight HES is hardly
ever used in Scandinavian ICUs, where HES 130/0.4 is
the preferred colloid [17] and 1
st choice fluid for
patients with severe sepsis (preliminary data from the
SAFE TRIP study, S Finfer, personal communication)
and septic shock [18].
At present there are very limited data on the effects of
HES 130/0.4 in septic patients. A single trial has been
published, in which 20 patients were randomised to
fluid resuscitation with either HES 130/0.4 or albumin
[19]. On the other hand, the effects of HES 130/0.4 on
coagulation and bleeding may be less pronounced than
those observed with HES 200/0.6 at least in the perio-
perative setting [14].
Taken together, two hypotheses can be put forward.
Resuscitation with high molecular weight HES may
cause AKF in patients with severe sepsis, or may
improve survival by up to 20% when compared to crys-
talloids. In any case, the low molecular weight HES 130/
0.4, which is in wide clinical use, is largely unstudied in
septic patients. Therefore, there is an urgent need for
trials on HES 130/0.4 in patients with severe sepsis.
Aims
To assess the effects of HES 130/0.4 compared with a
balanced crystalloid solution on mortality and end-stage
kidney failure on day 90 in patients with severe sepsis.
Methods/Design
Multicentre, randomised, double-blinded trial with con-
cealed allocation of septic patients 1:1 to fluid resuscita-
tion using 6% HES 130/0.4 in Ringer’s acetate
(Tetraspan, B Braun Medical AG, Melsungen, Germany)
or Ringer’s acetate (Sterofundin, B Braun Medical) stra-
tified by the presence of shock or not [8], haematologi-
cal malignancy or not [8] and inclusion in a university
hospital or not.
Tetraspan
Tetraspan contains hydroxyethylated starch 60 mg 130/
0.42 per ml and the isotonic electrolyte solution of
sodium chloride, potassium chloride, calcium chloride,
magnesium chloride, sodium acetate and malic acid. It
is marketed for the indication ‘treatment of imminent or
manifest hypovolaemia and shock’ in all the Nordic
countries (Summary of Product Characteristics for Tet-
raspan 6%, B Braun Medical).
Sterofundin
Sterofundin contains the isotonic electrolyte solution of
sodium chloride, potassium chloride, calcium chloride,
magnesium chloride, sodium acetate and malic acid. It
is marketed for the indication ‘treatment of extracellular
fluid loss by isotonic dehydration associated with mani-
fest or imminent acidosis’ in all the Nordic countries
(Summary of Product Characteristics for Sterofundin, B
Braun Medical).
Inclusion
All adult patients
￿ who need fluid resuscitation in the ICU
￿ AND who have fulfilled the criteria for severe sepsis
within the previous 24 hours according to the Society of
Critical Care Medicine/American College of Chest Phy-
sicians (SCCM/ACCP), see Additional file 1 [20]
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Page 2 of 9￿ AND where informed consent is obtainable either
from the patient or by proxy (In Denmark: Two physi-
cians followed by delayed consent from next of kin and
the patient’s general practitioner. In Iceland, Finland
and Norway: Next of kin)
The following patients will not be included:
￿ Age < 18 years
￿ Previously randomised in the 6S trial
￿ Allergy towards hydroxyethyl starch or malic acid
￿ Treatment with > 1000 ml of any synthetic colloid
within the last 24 hours prior to randomisation
￿ Any form of renal replacement therapy
￿ Acute burn injury > 10% body surface area
￿ Severe hyperkalaemia, p-K > 6 mM
￿ Liver or kidney transplantation during current hospi-
tal admission
￿ Intracranial bleeding within current hospitalisation
￿ Enrolment into another ICU trial of drugs with poten-
tial action on circulation, renal function or coagulation
￿ Withdrawal of active therapy
Randomisation
Staff at trial sites will have 24 hour access to a phone-
based, interactive, voice response randomisation system
at an independent trial unit (Copenhagen Trial Unit)
to allow immediate and concealed allocation and
intervention with trial fluid (see the randomisation
instruction generated by the eCRF, Figure 1). Randomi-
sation to trial fluid is performed in blocks (presence of
shock or not, haematological malignancy or not and
inclusion in a university hospital or not) with varying
block sizes according to the generation of the allocation
sequence by a computer at CTU. A unique identification
number of the patient will have to be entered into the
system to ensure that the same patient is not rando-
mised twice. In addition, each patient will be given a
unique patient-number and a randomisation number.
Primary outcome measure
The composite outcome measure of 90-day mortality or
end-stage kidney disease defined as dialysis-dependency
90 days after randomisation [21] will be the primary
outcome measure, and these two outcome measures will
also be analysed separately.
Secondary outcome measures
￿ Twenty-eight-day, 6-month and 1-year mortality
￿ Sepsis-related organ failure assessment (SOFA, mod-
ified from [22], see Additional file 2) score (excluding
Glasgow Coma Score) at day 5 after randomisation
￿ Kidney failure (SOFA score > 2 in the kidney com-
ponent) at any time in the ICU after randomisation
Figure 1 Screen print of the randomisation instruction generated by the web-based electronic case record form following successful
screening of a patient (all inclusion criteria fulfilled, no exclusion criteria fulfilled and consent obtained). Staff at trial sites will use this
instruction to call the phone-based, interactive, voice response randomisation system available around the clock at Copenhagen Trial Unit for
immediate and concealed allocation of the patient to trial fluid.
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nine values [3,4]) in the ICU after randomisation
￿ D e v e l o p m e n to fa c i d o s i sa sl o w e s tr e c o r d e da r t e r i a l
blood pH in the ICU after randomisation
￿ Need of renal replacement therapy within 90 days
after randomisation
￿ Need of mechanical ventilation within 90 days after
randomisation
￿ Days alive without renal replacement therapy in
90 days after randomisation
￿ Days alive without mechanical ventilation in 90 days
after randomisation
￿ Hospital length of stay for survivors sanctioned at
90 days after randomisation
Interventions
Trial fluid is to be used for volume expansion during
t h ee n t i r eI C U - s t a yf o ram a x i m u mo f9 0d a y s .T h e
treatment will follow the recommendations for fluid
therapy given by the Surviving Sepsis Campaign, see
Additional file 3 [1]. The maximum dose of HES 130/
0.4 recommended by the manufacturers is 50 ml/kg
ideal BW/24 hours. The maximum dose of trial fluid
will be 33 ml/kg ideal BW/24 hours as a recent retro-
spective study indicated that a dose of HES 130/
0.4 above this might increase the risk of kidney failure
in septic patients [23]. After that unmasked treatment
with Ringer’s acetate will be given to all patients (see
the trial fluid chart generated by the eCRF, Figure 2).
Maintenance fluids and nutrition should be given as
clinically indicated. Blood products should be given for
specific indications only as recommended by the Surviv-
ing Sepsis Campaign, see Additional file 3 [1]. The treat-
ing clinicians will decide all other interventions. As this
is a pragmatic trial, concomitant medication will not be
registered except for use of potentially nephrotoxic
drugs (see below).
The following will be done to reduce the risk of giving
too high doses of trial fluid:
￿ The maximum daily dose of trial fluid will be based
on estimated ideal body weight (men: estimated height
in cm - 100; women: estimated height in cm - 105).
￿ The calculated maximum daily dose of trial fluid will
be reduced to the nearest 500 ml.
￿ On the 1
st day of the trial, any synthetic colloids
given 24 hours prior to randomisation will be subtracted
the calculated dose of trial fluid.
If the patient is discharged and then readmitted to the
ICU within 90 days of randomisation the allocated trial
fluid must be used if volume expansion is indicated.
Figure 2 Trial fluid chart generated by the web-based electronic case record form following successful randomisation of a patient.
The fluid chart is to be used bed-side by clinical staff to ensure proper use of trial fluid and document the administration of trial fluid.
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T h et r i a lf l u i d sa r ev i s u a l l yi d e n t i c a la n dw i l lb ed e l i v -
ered in identical 500 ml ‘flexibag’ plastic bottles, which
will be put in black plastic bags and sealed by trial per-
sonnel not involved in randomisation or treatment of
patients. A computer program (CTU) will generate the
coding list with the numbers for the bottles. At rando-
misation, the computer program (CTU) will allocate
numbered bottles from the specific trial site to the
patient. Each trial site will have sufficient number of
bottles of trial fluid to be allocated to patients included.
This will ensure that the patient only receives the trial
fluid that he/she was randomised to receive.
Safety
Patients will be withdrawn from the trial fluid-treatment
protocol if
￿ Renal replacement therapy is commenced for acute
kidney failure OR
￿ SARs or SUSARs occur (see below)
Patients withdrawn from the trial fluid-treatment pro-
tocol for the above reasons will receive open-label saline
or Ringer’s lactate for volume expansion for the remain-
ing days of the 90-day study period.
The treating clinician can withdraw a patient from the
trial fluid-treatment protocol if
￿ The clinical status of the patient requires open-label
fluid treatment.
The independent Data Monitoring and Safety Com-
mittee - DMSC - will recommend pausing or stopping
the trial if (see Additional file 4 for details)
￿ Group-difference in the primary outcome measure is
found at the interim analysis
￿ Group-difference in 28- or 90-day mortality is found
at the interim analysis
￿ Group-difference in SARs or SUSARs is found at the
interim analysis
￿ Results from other trials show clear benefit or harm
with one of the trial fluids
Serious adverse reactions
The serious adverse reactions - SARs - described with
the use of the trial fluids are allergic reactions (both)
and bleeding (starch) (Tetraspan and Sterofundin Sum-
maries of Product Characteristics). The occurrence of
these will be recorded daily in the eCRF during the ICU
s t a ya n dc o m p a r e df o rt h et w ot r i a lg r o u p sb yt h e
DMSC at the interim analysis. An independent statisti-
cian will prepare the data for this. During the trial,
Sponsor will send a monthly report on the occurrence
of SARs to the DMSC and a yearly report to the ethics
committees.
Suspected unexpected serious adverse reactions (SUS-
ARs) will be defined as serious adverse reactions not
described in the Summaries of Product Characteristics
for Tetraspan and Sterofundin. SUSARs will be reported
by trial site investigators to Sponsor through the eCRF
within 24 h. Sponsor will report any SUSARs within
7 days to the medicines agency via EudraVigilance, to
the DMSC, which may request the randomisation status
of the patient, and to B. Braun Medical. During the trial,
Sponsor will send a monthly report on the occurrence
of SUSARs to the DMSC and a yearly report to the
ethics committees.
Serious adverse events (SAEs) will not be recorded as
an entity, because the majority of septic ICU patients
will experience SAEs during their critical illness. The
SAEs will be captured in the secondary outcome
measures.
Patient withdrawal
Patients who are withdrawn from the trial fluid-treat-
ment protocol (see Safety) will be followed up and ana-
lysed as the remaining patients.
Patients may be withdrawn from the trial at any time
if consent is withdrawn by the person(s), who has given
surrogate consent or by the patient. The person making
the withdrawal will be asked for permission to obtain
data for the primary outcome measure. If this person
declines, no more data will be collected (except in
Denmark and Finland where data for the primary out-
come measure will be collected centrally). All rando-
mised patients will be reported, and all data available
with consent will be used in the analyses. If appropriate,
multiple imputation will be used [24]. If there are
patients with missing data for the primary outcome
measure, new patients will be randomised to obtain the
full sample size.
Figure 3 Screen print of the first page of the screening part of
the web-based electronic case record form (eCRF)
(ExpertMaker, Lund, Sweden).
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withdrawn from the trial fluid-treatment protocol unless
this new ICU is an active trial site. If so the allocated
trial fluid will be used if volume expansion is indicated
in the new ICU. In any case, patients that are trans-
f e r r e dt oa n o t h e rI C Uw i l lb ef o l l o w e du pf o rt h e
primary outcome measure.
Statistics
Analysis will be by intention-to-treat comparing the
composite outcome measure of death or dialysis-depen-
d e n c ya t9 0d a y si nt h et w og r o u p sb yc h i - s q u a r e dt e s t
(the primary analysis) and multiple logistic regression
analysis adjusting for design and patient variables (strati-
fication variables, age, diabetes, use of nephrotoxic
drugs, previous renal dysfunction (’normal’ p-creatinine
>1 0 0μmol/l) [9], acute kidney failure at randomisation
(kidney failure (SOFA score ≥ 2 in the kidney compo-
nent) defining severe sepsis) [8] and SAPS II [9] and
SOFA score [8] in the 24 h where randomisation was
done according to the ICH guidelines [25].
2 × 400 patients will be needed to show a 20% RRR in
the composite outcome measure under the assumption of
a mortality of 45% (estimated from mean mortality rates
in the AT III meta-analysis [26], the two groups in
VISEP [4] and unpublished data from East Danish Septic
Shock Cohort, A Perner, personal communication) and
dialysis-dependency of 5% at 90 days [12,13], thus 50%
for the composite outcome measure, with an alpha of
0.05 (two-sided) and a power of 80%. With this sample
size an absolute reduction in the frequency of the com-
posite outcome measure from 50% to 40% can be shown.
An interim analysis will be performed after 400 patients.
The DMSC will recommend that the trial should be
stopped if it finds a group difference in primary outcome
measure, mortality, SARs or SUSARs with p ≤ 0.001 (Hay-
bittle-Peto criteria) [27,28] or otherwise find that the con-
tinued conduct of the trial clearly compromises patient
safety.
Data registration
Data will be entered into the web-based electronic case
record form (eCRF) (ExpertMaker, Lund, Sweden, Figure 3)
from patient notes (source) by trial or clinical personnel
under the supervision of the trial site investigators. From
the eCRFs the trial database (CTU) will be established.
Paper CRF will be used in case of technical difficulties with
the eCRF.
The following data will be registered:
Pre-randomisation characteristics (all obtained from
hospital notes):
National identification number, sex, age at randomisa-
tion, estimated height in cm, co-morbidities (previously
admitted for heart failure, myocardial infarction, stroke
or asthma or chronic obstructive pulmonary disease Y/
N, chronic treatment for arterial hypertension or dia-
betes Y/N, haematological malignancy Y/N, metastatic
cancer Y/N, AIDS Y/N, from where was the patient
admitted to the ICU? (emergency ward/general ward/
operation theatre or recovery/via paramedic or ambu-
lance services/other ICU this hospital/other hospital),
elective or emergency surgery within current hospital
admission Y/N, site of infection (pulmonary/abdominal/
urinary tract/soft tissue/other), and habitual p-creatinine.
Use of potential nephrotoxic drugs (Y/N) during current
hospital admission: IV gentamycin, IV vancomycin, IV
amphotericin B, IV polymyxins, ciclosporin A, IV con-
trast dye, NSAIDs and Cox-2 inhibitors.
24-hours prior to randomisation:
￿ Values for simplified acute physiology score (SAPS)
II [29]
￿ Volume of resuscitation fluids (crystalloids, colloids
and blood products specified in ml)
￿ Results of blood samples (standard lab. values) for
haemoglobin (lowest value), bilirubin (highest value),
INR (highest value), d-dimer (highest value) and plate-
lets (lowest value)
￿ Variables for SOFA scoring not covered above: Low-
est mean arterial blood pressure value and highest infu-
sion rate of vasoactive drugs
At randomisation (+/- 2 hours):
￿ Highest heart rate, lowest values of mean arterial
blood pressure, central venous pressure, central venous
oxygen saturation and highest values of arterial or
venous lactate concentration obtained from ICU charts
12-hourly in the first 24 after randomisation:
￿ Highest and lowest values of central venous pres-
sure, central venous oxygen saturation and arterial or
venous lactate concentration obtained from ICU charts
Daily in the first 5 days after randomisation:
￿ Results of morning samples of bilirubin, INR and
platelets (standard lab. values).
￿ Variables for daily SOFA scoring not covered above:
Lowest blood pressure value and highest infusion rate of
vasoactive drugs and lowest ratio of arterial oxygen ten-
s i o n / f r a c t i o no fi n s p i r e do x y g e no b t a i n e df r o mt h eI C U
charts
During the entire ICU stay:
￿ Daily volumes of trial fluid (reduced to aliquots of
250 ml) and other fluids including blood products,
nutrition, total fluid input, urinary output and calculated
fluid balance as of the ICU charts
￿ Daily lowest values of blood haemoglobin and arter-
ial pH and standard base excess (point of care testing)
and highest value of p-creatinine (standard lab. value)
￿ On mechanical invasive- or non-invasive ventilation
(as marked in the SOFA scoring day 0-5 and Y/N at
08.00 from day 6)
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￿ Any use of potential nephrotoxic drugs as men-
tioned above (Y/N for every day)
￿ Bleeding episodes noted in patient files including
gastrointestinal (haematemesis, frank blood or “coffee
grounds” in a nasogastric aspirate, or melaena or frank
blood in stools), wounds, during surgery or frank blood
in urine or tracheal aspirates.
￿ Serious adverse reactions (Y/N for every day) includ-
ing severe bleeding (intracranial bleeding or bleeding
episode (defined as above) with the need for ≥ 3u n i t s
of blood per day (defined as the 24 h of the units fluid
charge)) or serious allergic reactions defined as urticaria
associated with worsened circulation (20% decrease in
blood pressure or 20% increase in vasopressor dose),
increased airway resistance (20% increase in the peak
pressure on the ventilation or clinical stridor or bronch-
ospasme or treatment with bronchodilators).
90 days after randomisation:
￿ Survival status obtained from hospital or civil
registries
￿ If the patient is deceased, date of death
￿ Dialysis-dependency at day 90 defined as need of
renal replacement therapy within the time period 4 days
prior to or after day 90 post-randomisation as obtained
from hospital notes or registries.
￿ Total days of dialysis-dependency (any form of
haemo-dialysis or -filtration) summarised at day 90 from
hospital notes or registries. First and last treatment ses-
sion will define length of dialysis-dependency in each
patient.
￿ Date of hospital discharge as obtained from hospital
notes or registries
1/2- and 1 year after randomisation:
￿ Survival status obtained from hospital or civil
registries
Data handling and retention
Data will be handled according to the data protection
agencies of the different countries. All original records
(including consent forms, CRFs, SUSAR reports and
relevant correspondences) will be retained at trial sites
or CTU for 15 years to allow inspection by the GCP
Unit or local authorities. The study database will be
maintained for 15 years and anonymised if requested by
the authorities.
Monitoring
The trial will be externally monitored (the GCP unit at
University of Copenhagen) to GCP standards according
to the EU directive 2001/20. Trial site investigators will
give access to source data according to the Clinical Trial
Agreement.
Ethics
The trial will adhere to the Helsinki Declaration II and
the national laws in the Nordic countries. Inclusion
will start after approval by the ethical committees,
medicines agencies and data protection agencies in the
country of the trial site and trial registration at http://
www.clinicaltrials.gov.
Patients will only be enrolled after informed consent,
but the treatment has to be initiated immediately and
most patients will be unconscious and therefore
included after proxy consent according to national laws
(In Denmark: Two physicians followed by delayed con-
sent from next of kin and the patient’s general practi-
tioner. In Iceland, Finland and Norway: Next of kin).
The trial cannot be performed in conscious persons, as
no clinically relevant model of severe sepsis exists and no
conscious patients have the combination of severe infec-
tion and multiple organ failure as septic patients have.
No biological material will be collected for the trial,
thus no bio-bank will be formed.
Enrolment
The trial was registered 2009-08-09. Patients are
expected to be included from 30 Scandinavian ICUs
(Denmark 18 units, Sweden 5, Norway 3, Finland
3 units and Iceland 1 unit) during a 2-year period start-
ing 2009-12-23.
Each unit has to include 2 patients per month (holi-
days excluded) to finish inclusion in 2 years.
Presently (2010-08-15), 14 ICUs are active trial sites;
259 patients have been screened and 155 randomised.
Data analyses and publications
An independent statistician will perform the data analy-
sis prior to the breaking of the randomisation code.
Based on these masked analyses of the primary and sec-
ondary outcome measures two abstracts with conclu-
sions will be written by the Writing Committee, the
randomisation code will then be opened and a final
manuscript written containing the correct of the two
pre-made abstracts. The manuscript will be submitted
to one of the major clinical journals regardless of the
results. The Steering committee will grant authorship
depending on personal input (see Additional file 5)
according to the Vancouver definitions. All trial sites
and trial site investigators will be acknowledged. Fund-
ing sources will have no influence on data handling or
analysis or writing of the manuscript. Side studies will
be allowed if supported by the Steering committee.
Timeline
2008 - 2009: Applications for funding, ethical commit-
tees and medicines agencies, development of CRF and
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Page 7 of 9data management tools and development of monitoring
plan and education of monitors
2010 - 2011: Inclusion of patients
Mid 2011: Interim analysis
Early 2012: Data analyses, writing and submission of
the main manuscript for publication
Collaborators
Copenhagen Trial Unit, Centre for Clinical Intervention
Research, Rigshospitalet has developed the CRF together
with the Steering Committee and systems for phone-
based randomisation, allocation of trial fluid and data
handling.
The GCP unit at University of Copenhagen has devel-
oped the monitoring plan and coordinated the monitor-
ing in collaboration with the GCP units in Aarhus,
Odense, Lund and Oslo.
The Scandinavian Society of Anaesthesia and Intensive
Care provides the platform for web-based data entry -
the eCRF (ExpertMaker AB, Lund, Sweden).
B Braun Medical AG (Melsungen, Germany) delivers
trial fluids to all trial sites.
Finances
T h et r i a li sf u l l yf u n d e db yt h eD a n i s hS t r a t e g i c
Research Council, the Danish Research Council, Rig-
shospitalet, the ACTA foundation and resources at trial
sites. The funding sources have no influence on the trial
design or data collection, management, analysis or
reporting. The patients are covered by local insurance at
the trial sites.
Perspective
Severe sepsis affects millions of patients worldwide with
high rates of complications and mortality. Outcome dif-
ferences between therapies for severe sepsis will, there-
fore, have major impact on global health and healthcare
costs.
Currently, three other RCTs are assessing the effects
of HES 130/0.4 in sepsis:
BASES is a single centre study expected to include
250 patients with severe sepsis. The primary outcome
measure is ICU length of stay, but mortality and the fre-
quency of renal replacement therapy is also recorded
(clinicaltrial.gov identifier: NCT00273728). Recruitment
is expected to be completed in May 2010 (M Siege-
mund, personal communication).
CRYSTMAS is a multicentre study expected to
include 200 patients with severe sepsis. The primary
outcome measure is amount of fluid required to achieve
initial haemodynamic stabilisation and amount of ent-
eral calories given in the 7 days after stabilisation,
but markers of organ failure will also be recorded.
Recruitment has been stopped in March 2010 (clinical-
trial.gov identifier: NCT00464204).
CHEST is an Australian/New Zealand multicentre
RCT comparing HES 130/0.4 and saline in 7,000 hypovo-
laemic ICU patients (clinicaltrial.gov identifier:
NCT00935168). The primary outcome measure is 90-
day mortality and subgroup analysis of patients with
severe sepsis is planned (J Myburgh, personal communi-
cation). We collaborate with the investigators and plan a
common individual patient data meta-analysis combin-
ing our data with those of their patients with severe sep-
sis (1,000 expected). Thus inclusion and exclusion
criteria and outcome measures of the two trials have
been harmonised to prepare for the common analysis.
Even though none of the trials alone may be definitive
in answering the questions regarding safety and efficacy
of HES 130/0.4 in patients with severe sepsis, the results
will form the basis for meta-analysis of data from more
than 2,000 septic patients.
Discussion
The 6S trial will provide important safety and efficacy
data on the use of HES 130/0.4 in patients with severe
sepsis.
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